KR20240004887A - 고전도도의 칼륨 채널 조정제, 이의 조성물, 이의 제조 방법, 및 이의 사용 방법 - Google Patents

고전도도의 칼륨 채널 조정제, 이의 조성물, 이의 제조 방법, 및 이의 사용 방법 Download PDF

Info

Publication number
KR20240004887A
KR20240004887A KR1020237041640A KR20237041640A KR20240004887A KR 20240004887 A KR20240004887 A KR 20240004887A KR 1020237041640 A KR1020237041640 A KR 1020237041640A KR 20237041640 A KR20237041640 A KR 20237041640A KR 20240004887 A KR20240004887 A KR 20240004887A
Authority
KR
South Korea
Prior art keywords
substituted
bond
alkyl
diyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041640A
Other languages
English (en)
Korean (ko)
Inventor
조셉 브이. 페르골리치
로버트 비. 라파
Original Assignee
에날레어 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에날레어 테라퓨틱스 인크. filed Critical 에날레어 테라퓨틱스 인크.
Publication of KR20240004887A publication Critical patent/KR20240004887A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • C07D251/70Other substituted melamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
KR1020237041640A 2021-05-04 2022-05-04 고전도도의 칼륨 채널 조정제, 이의 조성물, 이의 제조 방법, 및 이의 사용 방법 Pending KR20240004887A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183717P 2021-05-04 2021-05-04
US63/183,717 2021-05-04
PCT/US2022/027637 WO2022235771A1 (en) 2021-05-04 2022-05-04 Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20240004887A true KR20240004887A (ko) 2024-01-11

Family

ID=83932518

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041640A Pending KR20240004887A (ko) 2021-05-04 2022-05-04 고전도도의 칼륨 채널 조정제, 이의 조성물, 이의 제조 방법, 및 이의 사용 방법

Country Status (10)

Country Link
US (1) US20240238303A1 (https=)
EP (1) EP4333852A4 (https=)
JP (1) JP2024516730A (https=)
KR (1) KR20240004887A (https=)
CN (1) CN117479945A (https=)
AU (1) AU2022270648A1 (https=)
BR (1) BR112023023075A2 (https=)
CA (1) CA3217887A1 (https=)
MX (1) MX2023013065A (https=)
WO (1) WO2022235771A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1330426A4 (en) * 2000-10-13 2005-09-14 Bristol Myers Squibb Co SELECTIVE MAXI-K CALIUM CHANNEL OPENING OPERATORS UNDER CONDITIONS OF HIGH INTRA-CELLULAR CALCIUM CONCENTRATIONS, METHOD AND THEIR USE
ATE488231T1 (de) * 2002-12-23 2010-12-15 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
JP2007505158A (ja) * 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼC−μ(PKD)の阻害
US20090111868A1 (en) * 2004-12-02 2009-04-30 Marx Steven O Use Of Rottlerin And Its Derivatives As Activators Of BK Channel For Therapy Of Hypertension And Related Disorders
US8399663B2 (en) * 2009-04-03 2013-03-19 Astellas Pharma Inc. Salt of 1,3,5-triazine-2,4,6-triamine derivative
US20100256152A1 (en) * 2009-04-03 2010-10-07 Astellas Pharma Inc. Novel pharmaceutical composition for treatment of schizophrenia
GB201011905D0 (en) * 2010-07-15 2010-09-01 Unilever Plc Benefit delivery particle,process for preparing said particle,compositions comprising said particles and a method for treating substrates
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
SG11201407964YA (en) * 2012-05-29 2014-12-30 Galleon Pharmaceuticals Inc Novel compounds and compositions for treatment of breathing control disorders or diseases
SG11201503505QA (en) * 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
GB201408119D0 (en) * 2014-05-08 2014-06-25 Univ Cork Method
WO2018007331A1 (en) * 2016-07-08 2018-01-11 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
WO2018011164A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
CN108276410B (zh) * 2017-01-06 2021-12-10 首药控股(北京)股份有限公司 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
CN117479945A (zh) 2024-01-30
MX2023013065A (es) 2024-01-03
BR112023023075A2 (pt) 2024-01-30
EP4333852A1 (en) 2024-03-13
EP4333852A4 (en) 2025-03-26
CA3217887A1 (en) 2022-11-10
AU2022270648A1 (en) 2023-12-07
US20240238303A1 (en) 2024-07-18
JP2024516730A (ja) 2024-04-16
WO2022235771A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
US20250114370A1 (en) Methods and compositions for treating drug overdose
JP2025511227A (ja) 呼吸器刺激性経鼻製剤
US20250032496A1 (en) Methods of treating respiratory depression modulated by a non-opioid agent
KR102382188B1 (ko) NamPT 억제용 신규 화합물 및 이를 포함하는 조성물
EP3444249B1 (en) Sodium channel blockers, preparation method thereof and use thereof
US20250031718A1 (en) Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
JP2025501169A (ja) 呼吸刺激薬非経口製剤
KR20240004887A (ko) 고전도도의 칼륨 채널 조정제, 이의 조성물, 이의 제조 방법, 및 이의 사용 방법
US20230414624A1 (en) Methods of treating neurological ventilatory insufficiency
TW202529771A (zh) 用於治療藥物過量的方法及組合物
CN118829433A (zh) 呼吸刺激剂肠胃外制剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231201

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250502

Comment text: Request for Examination of Application